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Abstract
BACKGROUND—The clinical recognition of cardiometabolic disorders might be enhanced by 
anthropometry based on the sagittal abdominal diameter (SAD; also called “abdominal height”) or 
waist circumference rather than on weight. Direct comparisons of body mass index (BMI, weight/
height2) with SAD/height ratio (SADHtR) or waist circumference/height ratio (WHtR) have not 
previously been tested in nationally representative populations.
METHODS—Nonpregnant adults without diagnosed diabetes (ages 20–64 years; n = 3071) 
provided conventional anthropometry and supine SAD (by sliding-beam caliper) in the 2011–2012 
US National Health and Nutrition Examination Survey. Population-weighted, logistic models 
estimated how strongly each anthropometric indicator was associated with 5 cardiometabolic 
disorders: Dysglycemia (glycated hemoglobin ≥5.7%), HyperNonHDLc (non-high-density-
lipoprotein [HDL] cholesterol ≥4.14 mmol/L, or taking anticholesteremic medications), 
Hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, or 
taking antihypertensive medications), HyperALT (alanine transaminase ≥p75 [75th percentile, sex-
specific]), and HyperGGT (gamma-glutamyltransferase ≥p75 [sex-specific]).
RESULTS—After scaling each indicator, adjusted odds ratios (aORs) tended to be highest for 
SADHtR and lowest for BMI when identifying each disorder except dysglycemia. When SADHtR 
entered models simultaneously with BMI, the aORs for BMI no longer directly identified any 
condition, whereas SADHtR identified persons with HyperNonHDLc by aOR 2.78 (95% 
confidence interval [CI], 1.71–4.51), Hypertension by aOR 2.51 (95% CI, 1.22–5.15), HyperALT 
by aOR 2.89 (95% CI, 1.56–5.37), and HyperGGT by aOR 5.43 (95% CI, 3.01–9.79). WHtR 
competed successfully against BMI with regard to Dysglycemia, Hyper-NonHDLc, and 
HyperGGT. c-Statistics of SADHtR and WHtR were higher than those of BMI (P <.001) for 
identifying HyperNonHDLc and HyperGGT.
CONCLUSIONS—Among nonelderly adults, SADHtR or WHtR recognized cardiometabolic 
disorders better than did the BMI.
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Since 1980, epidemiologists and many clinicians have identified persons with excess 
adiposity by calculating their body mass index (BMI; kg/m2).1 Nevertheless, commentators 
have pointed out that increased weight may represent lean tissues as well as fat mass,2 or 
that adipose tissue accumulated in non-truncal regions (eg, gluteofemoral) may be relatively 
benign in comparison with adipose tissue in the abdominal depots.3 Some authorities 
recommend that the waist circumference be added to BMI as a primary tool for assessing 
adiposity.4,5
CLINICAL SIGNIFICANCE
• For identifying 5 cardiometabolic disorders, body mass index was no better 
than sagittal abdominal diameter (SAD)/height or waist/height ratios.
• The SAD/height ratio may perform best for finding hypertension, elevated 
alanine transaminase, or gamma-glutamyltransferase.
During the past 2 decades, the prevalence of abdominal adiposity among US women and 
overweight men has increased, irrespective of BMI categories.6 This trend in body fat 
distribution suggests a need for alternative approaches to anthropometry in clinical and 
epidemiologic settings. Rather than concentrate on total body weight, examiners might focus 
on external measurements of the abdomen. The waist circumference has been widely 
employed as a proxy measure of abdominal adipose tissue,7,8 although the waist 
circumference/height ratio (WHtR) may represent an anthropometric improvement because 
it roughly controls for variation in adult stature.9–11 Neither waist circumference nor WHtR, 
however, distinguishes between adipose tissue accumulated within, as opposed to outside, 
the visceral compartment.
The supine sagittal abdominal diameter (SAD, also described as “abdominal height”) 
arguably estimates intra-abdominal adipose tissue better than the waist circumference.12–14 
Recent studies reported that SAD was more strongly associated than waist circumference 
with men’s atherogenic lipoprotein subfractions15 or women’s insulin resistance.16 Studies 
in selected research samples have reported that the SAD/height ratio (SADHtR) also could 
serve to identify cardiometabolic risk.17,18
Any discussion of whether to adopt WHtR or SADHtR more widely would first require 
confirmation that these indicators are indeed associated with known cardiometabolic risk 
factors in a representative population. Thereafter, it would help to demonstrate that these 
associations are independent of BMI, and that they might be of superior strength. In 2011–
2012, the National Health and Examination Survey (NHANES) began measuring the supine 
SAD.19 Simultaneous measurements of weight, height, and waist circumference were 
obtained, along with clinical and laboratory information that established aspects of 
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cardiometabolic risk. These cross-sectional data drawn from a large, representative sample 
of nonelderly adults have allowed us to assess how well the adiposity indicators SADHtR, 
WHtR, and BMI are associated with 5 common cardiometabolic disorders.
METHODS
Survey Participants and Their Measurements
NHANES is an ongoing, nationally representative, cross-sectional survey of the resident 
civilian, noninstitutionalized, US population.20 Participants chosen for NHANES undergo 
home interviews followed by standardized anthropometric and laboratory assessments in 
mobile examination centers. The NHANES protocol was approved by the Research Ethics 
Review Board of the National Center for Health Statistics; participants provided informed 
consent. Our report is restricted to participants from 2011–2012.
We excluded those who responded afirmatively to the question “Have you ever been told by 
a doctor or other health professional that you have diabetes or sugar diabetes?” (for women 
“…other than during pregnancy”). By restricting analysis to adults without diagnosed 
diabetes, we attempted to minimize confounding by behaviors or medication use that might 
influence adiposity indicators or the cardiometabolic disorders of interest. We defined adults 
as individuals ≥20 years old, but we excluded pregnant women and those ≥65 years out of 
concern primarily for survivorship bias. Also excluded were 787 eligible participants who 
lacked information on SAD, waist circumference, BMI, or the clinical information required 
to confirm the 5 cardiometabolic disorders described in the following paragraph. After these 
exclusions, our analytic sample included 3071 nonelderly, nonpregnant adults without 
diagnosed diabetes.
For analytic modeling, we chose as dependent variables 5 
cardiometabolicdisorders(Dysglycemia,21 HyperNonHDLc,22–24 Hypertension,25–27 
HyperALT,28–30 and HyperGGT31–34) that could be easily identified in the NHANES data 
(see Table 1 for the definition of each condition).
Online documents describe the pertinent laboratory and blood-pressure measurements 
acquired by NHANES.35 Within our represented study population, the 75th percentile (p75) 
thresholds for HyperALT were 33 U/L for men, 22 U/L for women; for HyperGGT they 
were 33 U/L for men, 21 U/L for women. Blood pressure values were the means of second 
and third readings. Medication use was ascertained from responses to the questions “To 
lower your blood cholesterol, are you now following advice to take prescribed medicine?” or 
“Are you now taking prescribed medicine for your high blood pressure/hypertension?”
SAD was measured using a portable, sliding-beam caliper (Holtain, Ltd, Wales, UK).19,36 
Supine participants rested on a lightly padded examination table with their hips in fiexed 
position as the examiner marked the level of their iliac crests. The lower arm of the caliper 
was then positioned under the small of the back, and the upper arm was raised above the 
belly in alignment with their iliac-crest level. The examiner asked the participant to inhale 
gently, slowly let the air out, and then relax. The examiner then lowered the caliper’s upper 
arm, letting it lightly touch the abdomen but without compressing it. The SAD value was 
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read directly from a centimeter scale on the caliper shaft, recorded to the nearest 0.1 cm. For 
94.4% of the participants we defined SAD as the mean of 2 initial measurements; for 5.6% 
we used the mean of up to 4 measurements.37 Weight, height, and waist circumference 
(standing position, just above the iliac crest) were measured by established methods.36
Statistical Analyses
NHANES selected participants through a complex, multistage-probability design requiring a 
sampling weight for each participant. We used SAS (release 9.3; SAS Institute Inc., Cary, 
NC) and SUDAAN (release 11.1; RTI International, Research Triangle Park, NC) to account 
for the complex design and sampling weights so that characteristics of the represented 
population could be correctly described.
We compared the strengths of the adiposity indicators using 3 approaches. Our initial 
approach prepared separate, sex-stratified, multivariable, logistic regression models (RLO-
GIST procedure of SUDAAN) to evaluate SADHtR, WHtR, or BMI as alternative 
independent variables. In order to compare the magnitude of adjusted odds ratios (aORs) 
from these alternative models, we scaled each adiposity indicator according to its sex-
specific interquartile range (75th percentile [p75] minus 25th percentile [p25]) in the 
estimated population. Each model included adjustments for age (continuous), age,2 and a 
quadratic term for the adiposity indicator. An additional term adjusted for self-identified race 
and ethnicity summarized in 5 mutually exclusive ancestral categories (non-Hispanic white, 
non-Hispanic black, non-Hispanic Asian, Hispanic, and “other, including multi-racial”). For 
outcome disorders HyperNonHDLc and Hypertension, we also repeated these sex-stratified 
modeling exercises after excluding persons who reported current use of the medication class 
prescribed to control that condition.
Our second approach tested whether an adiposity indicator might retain its independent 
association with the outcome while another indicator, despite recognized collinearity, was 
competing simultaneously in the model. For direct comparisons against the BMI, we 
prepared expanded logistic models in which the scaled BMI and the scaled SADHtR (along 
with their quadratic terms) were both participating. Similar logistic models tested the BMI in 
competition with the WHtR, or the SADHtR in competition with WHtR, for each 
cardiometabolic disorder. These models with 2 simultaneous indicators retained the 
covariates for age, age,2 and ancestry. For the competing adiposity indicators in this report 
we present the simultaneous odds ratios based on the full sample of men and women. These 
models also included a covariate for sex, except for HyperALT and HyperGGT, in which 
outcome thresholds were defined in a sex-specific manner.
Our third approach calculated a c-statistic (area under the curve of the receiver operating 
characteristic [ROC]) and its jackknife variance. This approach covered a full range of 
discrimination thresholds for each continuous independent variable, and did not depend on 
scaling each indicator to its interquartile range. We used the “somersd” procedure in STATA 
(version 13; StataCorp LP, College Station, TX) to calculate each c-statistic for the sample 
of men plus women, with adjustment for 5 ancestral groups, using restricted cubic splines (3 
knots) for each adiposity indicator and age. A sex adjustment was included when the 
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outcome condition was Dysglycemia, HyperNonHDLc, or Hypertension. We conducted 
pairwise comparisons of the c-statistics (goodness of fit) by the “lincom” function.
RESULTS
Population Distributions of Cardiometabolic Disorders and Adiposity Indicators
Prevalence estimates for the outcome disorders in our represented population ranged from 
21.5% (Hypertension in women) to 42.4% (HyperNonHDLc in men) (Table 1). Table 2 
shows the sex-stratified population distributions of age and adiposity indicators. Women 
tended to have a wider dispersion of the anthropometric variables, with the exception of 
height, as shown by their larger interquartile ranges.
Individual Adiposity Indicators Associated with Each Cardiometabolic Disorder (by Sex)
Each of the scaled adiposity indicators was associated with all 5 of the cardiometabolic 
disorders. Among men, the weakest associations were with Dysglycemia (aOR point 
estimates 1.59 to 1.60), and the strongest were with HyperALT (aORs 3.30 to 4.02) (Figure 
1). Among women, the aORs fell in a narrower range (1.51 to 2.42) across all 5 of the 
cardiometabolic disorders.
For HyperNonHDLc, Hypertension, HyperALT, and HyperGGT, the aORs tended to be 
largest for the scaled SADHtR and lowest for scaled BMI. The aORs for scaled WHtR 
generally had intermediate values. (See Supplemental Table 1, available online for exact 
aORs and 95% confidence intervals [CIs] associated with each model). Among these 4 
cardiometabolic disorders for men (Figure 1), the largest aOR was 4.02 (SADHtR to identify 
HyperALT), while the smallest aOR was 1.67 (BMI to identify HyperNonHDLc). For 
women, the largest aOR was 2.42 (SADHtR to identify HyperGGT), while the smallest was 
1.51 (BMI to identify HyperNonHDLc).
With regard to outcome disorders other than Dysglycemia, some adiposity indicators had 
significant curvilinear relationships (P <.05 for quadratic terms). These instances are 
identified in Supplemental Table 1, available online).
When we excluded persons whose HyperNonHDLc was defined by currently taking 
anticholesteremic medication, the rankings of adiposity indicators were similar (ie, SADHtR 
> WHtR > BMI). In this analysis of a reduced population, the prevalence of 
HyperNonHDLc decreased to 36.4% for men, and their aORs were 2.24 for SADHtR, 2.14 
for WHtR, and 1.70 for BMI. The prevalence of Hyper-NonHDLc decreased to 27.7% for 
women, and their aORs were 2.02 for SADHtR, 2.00 for WHtR, and 1.51 for BMI. When 
we excluded persons whose Hypertension was defined by currently taking antihypertensive 
medication, the prevalence of Hypertension in this reduced population decreased to 10.4% 
for men, and their aORs were 2.38 for SADHtR, 2.04 for WHtR, and 1.75 for BMI. The 
prevalence of Hypertension decreased to 6.1% for women, and their aORs were 1.73 for 
SADHtR, 1.64 for WHtR, and 1.59 for BMI.
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Competing Adiposity Indicators Associated with Each Cardiometabolic Disorder (Sexes 
Combined)
In our multivariable logistic models with competing (simultaneous) terms for SADHtR and 
BMI, the BMI was unable to positively identify any of the cardiometabolic disorders. In this 
competing situation, SADHtR identified persons with Hyper-NonHDLc by aOR (95% CI) 
2.78 (1.71–4.51), Hypertension by aOR 2.51 (1.22–5.15), HyperALT by aOR 2.89 (1.56–
5.37), and HyperGGT by aOR 5.43 (3.01–9.79), but did not identify persons with 
Dysglycemia (aOR 1.44 [0.92–2.25]) (Figure 2 and Supplemental Table 2, available online). 
In these models based on the combined sexes, being male contributed to HyperNonHDLc 
(aOR 1.5; P = .007), but did not significantly influence the other 4 outcomes.
When WHtR competed simultaneously with BMI, once again BMI lost the ability to 
positively identify any of the cardiometabolic disorders (Figure 3 and Supplemental Table 2, 
available online). The WHtR identified persons with Dysglycemia by aOR 1.67 (95% CI, 
1.06–2.62), HyperNonHDLc by aOR 3.87 (95% CI, 2.14–7.01), and HyperGGT by aOR 
4.71 (95% CI, 1.68–13.2), but did not identify persons with Hypertension (aOR 1.93; 95% 
CI, 0.96–3.85) or with HyperALT (aOR 1.63; 95% CI, 0.77–3.44).
In models that directly compared SADHtR with WHtR, we found for all 5 cardiometabolic 
disorders that the aORs for WHtR were indistinguishable from 1.00 (Supplemental Table 2, 
available online). SADHtR likewise became a nonsignificant term for identifying 
Dysglycemia and HyperNonHDLc. However, in simultaneous competition with WHtR, 
SADHtR continued to identify Hypertension (aOR 2.42; 95% CI, 1.00–5.89), HyperALT 
(aOR 3.75; 95% CI, 1.81–7.74), and HyperGGT (aOR 3.06; 95% CI, 2.08–4.52).
c-Statistics for Individual Adiposity Indicators and Their Comparisons (Sexes Combined)
Calculated c-statistics (areas under the ROC curve [95% CI]) ranged from a high value of 
0.812 [0.788–0.835] for Hypertension identified by SADHtR to a low value of 0.664 
[0.636–0.691] for HyperGGT identified by BMI (Table 3). For identification of 
HyperNonHDLc and HyperGGT, the c-statistics for SADHtR and WHtR were higher (P <.
001) than those for BMI. For all 5 of the outcomes, the c-statistics for SADHtR tended to be 
higher than those for WHtR, but these differences did not reach statistical significance.
DISCUSSION
In this representative, cross-sectional, population sample we found that the SADHtR and 
WHtR provided some advantages over BMI for identifying persons with 5 cardiometabolic 
disorders. SADHtR competed successfully against BMI for 4 of the 5 disorders (Figure 2, 
Supplemental Table 2, available online), and WHtR competed successfully against BMI for 
3 of the 5 disorders (Figure 3, Supplemental Table 2, available online). We found no 
instances in which the BMI had advantages over SADHtR or WHtR.
In models that simultaneously compared SADHtR with WHtR, these 2 indicators were 
roughly equivalent for identifying Dysglycemia and HyperNonHDLc; however, SADHtR 
remained independently capable of identifying Hypertension, HyperALT, and HyperGGT 
(Supplemental Table 2, available online). When comparing their c-statistics (overall 
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goodness of fit), SADHtR and WHtR were each superior to BMI for identifying 
HyperNonHDLc or HyperGGT (Table 3).
SADHtR and WHtR are proxy indicators for enlargement of abdominal adipose tissue while 
roughly controlling for stature. However, it is expansion more specifically of the intra-
abdominal adipose tissue that reflects the dyslipidemic, hormonal, and inflammatory 
features that constitute dysfunctional adiposity.5,7,38–40 SADHtR is presumably the better 
estimator of expanded intra-abdominal adipose tissue. By contrast, WHtR also incorporates 
an estimate of the abdominal subcutaneous adipose tissue, which generally performs 
relatively benign functions. Subcutaneous adipose tissue serves primarily as a metabolic sink 
during periods of caloric excess and as the source of necessary fuels when they are 
required.41,42 However, when subcutaneous adipose tissue does not adequately expand to 
sequester excessive circulating fatty acids, the intra-abdominal adipose tissue sites become 
further enlarged.27,43,44 Smaller depots of adipose tissue (eg, epicardial, perivascular, renal 
sinus) may likewise expand under these circumstances, and these expansions are associated 
with adverse consequences for, respectively, the heart, great vessels, or renal function.45,46 
In addition, excessive caloric intake may be directed to organs (liver, skeletal muscle, 
pancreas, and myocardium) where “ectopic” lipid accumulation in these nonadipose tissues 
can alter usual cellular metabolism.47,48 The magnitude of lipid accumulation in these small 
depots or ectopic sites, however, cannot be estimated directly except by costly imaging or 
spectroscopic technologies. These considerations support the logic of quantifying 
dysfunctional adiposity primarily through an external, inexpensive estimate of intra-
abdominal adipose tissue accumulation.
In recent years, external abdominal anthropometry has primarily depended on the waist 
circumference7,8 or the WHtR.9–11 Reports employing the SADHtR have been 
infrequent,17,18 but among Finnish adults (ages ≥30 years) the population-based distribution 
of SADHtR has been described from a national survey conducted in 2000–2001.49 The 
Finnish distributions of SADHtR resembled the US distributions in 2011–2012, reported 
here in Table 2.
While the SAD is an unfamiliar dimension to many clinicians, its measurement by a sliding-
beam caliper can be no more complex or expensive than the accurate measurement of body 
weight. SAD requires an examination table and a portable caliper, whereas weight 
measurement requires the presence and regular calibration of a good-quality scale. For the 
SAD measurement, clothing must be loosened sufficiently to expose the mid-abdominal 
area, but there is no need to empty pockets or to remove outer garments, shoes, heavy 
jewelry, or most medical appliances. The amputation of a limb ordinarily limits the utility of 
a weight measurement, but this is rarely true for the SAD. The SAD protocol requires 
attention to the phases of respiration. Measurement of the standing waist circumference 
likewise requires attention to respiratory phases, along with methods to standardize the 
tension applied to the measuring tape and ensure its horizontal orientation at the specified 
position on the abdomen.
Our report is limited by the absence in NHANES 2011–2012 of circumferences measured at 
the hip or thigh. If these circumferences had been obtained, these data might have been used 
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to calculate the waist/hip ratio,50 the waist-hip-height ratio,18 or the SAD/thigh 
circumference ratio.51 Each of these adiposity indicators has been reported to predict 
incident cardiovascular disease in prospective studies.
Anthropometry repeated over time could test the value of SADHtR or WHtR for monitoring 
changes in cardiometabolic risk, but NHANES does not include any longitudinal 
anthropometric data. A recent report from the MESA Study,40 however, has demonstrated 
that changes of intra-abdominal adipose tissue (as measured by sequential computed 
tomography images) are superior to changes in weight for the prediction of future 
cardiometabolic outcomes.
We would like also to have considered outcome variables that are usually measured in the 
fasting state. However, fasting blood was obtained in NHANES only from participants 
attending the morning examination sessions. The reduced sample size for these fasting 
variables provided insufficient outcome information to yield reliable results.
The NHANES is an ongoing program providing public-access information collected in 2-
year examination cycles from representative US population samples.20 With the continued 
availability of SAD measurements in NHANES, researchers will have opportunities to 
validate our results with larger sample sizes and outcome biomarkers that require fasting 
blood samples. We anticipate increasing interest in the uses of abdominal anthropometry to 
estimate chronic-disease risks in the USA.
Supplementary Material
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Comparisons in the population for men (panel A) and women (panel B) among SADHtR, 
WHtR, and BMI in association with 5 cardiometabolic disorders. Each adiposity indicator is 
scaled to the sex-specific interquartile range. Adjusted odds ratios (aOR; with 95% 
confidence intervals) are plotted logarithmically on the Y-axis. ALT = alanine transaminase; 
BMI = body mass index; GGT = gamma-glutamyltransferase; HDL = high-density 
lipoprotein; SADHtR = sagittal abdominal diameter/height ratio; WHtR = waist 
circumference/height ratio.
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Comparisons of adjusted odds ratios (95% confidence intervals) for SADHtR and BMI as 
they compete simultaneously in models identifying 5 cardiometabolic disorders. The 
estimated population includes both sexes, and each adiposity indicator is scaled to its sex-
specific interquartile range. Y-axis values are plotted logarithmically. aOR = adjusted odds 
ratio; BMI = body mass index; GGT = gamma-glutamyltransferase; HDL = high-density 
lipoprotein; SADHtR = sagittal abdominal diameter/height ratio.
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Comparisons of adjusted odds ratios (95% confidence intervals) for WHtR and BMI as they 
compete simultaneously in models identifying 5 cardiometabolic disorders. The estimated 
population includes both sexes, and each adiposity indicator is scaled to its sex-specific 
interquartile range. Y-axis values are plotted logarithmically. aOR = adjusted odds ratio; 
BMI = body mass index; GGT = gamma-glutamyltransferase; HDL = high-density 
lipoprotein; WHtR = waist circumference/height ratio.
Kahn and Bullard Page 14

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Am J Med. Author manuscript; available in PMC 2017 February 06.
